2,4-dichlorocinnamyl chloride | 77975-44-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,4-dichlorocinnamyl chloride
• 英文别名: 1-Chloro-3-(2,4-dichlorophenyl)prop-2-ene；2,4-dichloro-1-[(E)-3-chloroprop-1-enyl]benzene
• CAS: 77975-44-1
• 化学式: C₉H₇Cl₃
• 分子量: 221.514
• InChiKey: AFLBPVZOGNDRFH-OWOJBTEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  2,4-dichlorocinnamyl chloride 、 咪康唑 以 异丙醚 、 乙腈 为溶剂， 生成 1-(2,4-dichlorocinnamyl)-3-[2,4-dichloro-β-(2,4-dichlorobenzyloxy)phenethyl]-imidazolium chloride
  参考文献：
  名称：

  Imidazolium salts

  摘要：

  新型的四元咪唑盐，其中咪唑阳离子的一个氮原子上取代有一个##EQU1##基团，其中每个A是芳基基团，B是脂肪基、芳基取代的脂肪基或芳基基团，这些盐可用作抗微生物剂。

  公开号：

  US03991202A1
• 作为产物：
  描述：

  反-2,4-二氯肉桂酸 在 吡啶 、 sodium tetrahydroborate 、 氯化亚砜 作用下， 以 1,4-二氧六环 、 苯 为溶剂， 反应 84.0h， 生成 2,4-dichlorocinnamyl chloride
  参考文献：
  名称：

  吡唑并[3,4-d]嘧啶核糖核苷作为抗球虫药。3.4-[（（芳基烯基）硫代]吡唑并[3，4-d]嘧啶的一些核苷的合成和活性。

  摘要：

  4-（烷硫基）-1H-吡唑并[3,4-d]嘧啶的核糖核苷已被证明是有用的抗球虫药[Krenitsky，TA; 骑乘，JL；GW科萨尔卡；Inmon，RB；赵安永; GB Elion；VS 威廉姆斯，RBJ Med。化学 1982，25，32。TA Krenitsky；Elion，GBUS专利4299 283，1981]。在那项研究中，不饱和的4-烯丙基硫代和4-巴甲基硫代衍生物（19和20）在体内对艾美球虫的活性比其饱和同类物更具活性。因此，合成了一些不饱和的（芳烷基）硫代衍生物，并作为抗球虫剂进行了研究。本研究中的新化合物（2至18）是通过将4-巯基-1-β-D-呋喃呋喃糖基-1H-吡唑并[3,4-d]嘧啶（1）烷基化制备的（1）方法。（E）-4-肉桂硫基衍生物（2）和5'-单磷酸酯（18）是体内对抗大肠杆菌的最具活性的化合物。在体内，在芳基部分（3至13）中具有取代基的类似物没有一个比

  DOI：

  10.1021/jm00364a024

文献信息

• Pyridazine compounds and compositions containing the same
  申请人：Kowa Co., Ltd.

  公开号：US06348468B1

  公开（公告）日：2002-02-19

  This invention relates to pyridazine derivatives represented by the formula (1): wherein R1 represents a (substituted) aryl group, R2 represents a phenyl group substituted at 4-position by a lower alkoxyl group or a lower alkylthio group, R3 represents a lower alkoxyl group, a halogenated lower alkyl group, a lower cycloalkyl group, a (subsituted) aryl group, a (substituted) aryloxy group, a (substituted) nitrogen-containing heterocyclic ring residue, a (substituted) aminocarbonyl group or a lower alkylcarbonyl group, A represents a single bond, a lower alkylene group or a lower alkenylene group, X represents O or S, and the dashed line indicates that the carbon-carbon bond between the 4-position and the 5-position is a single bond or a double bond, or salts thereof; and also to medicines containing them as effective ingredients. These compounds have excellent inhibitory activity against interleukin-1&bgr; production, and are useful as preventives and therapeutics for immune system diseases, inflammatory diseases, ischemic diseases and the like.

  这项发明涉及由式（1）表示的吡啶嗪衍生物： 其中R1代表（取代的）芳基，R2代表在4位被低烷氧基或低烷硫基取代的苯基，R3代表低烷氧基、卤代低烷基、低环烷基、（取代的）芳基、（取代的）芳氧基、（取代的）含氮杂环环残基、（取代的）氨基羰基或低烷基羰基，A代表单键、低烷基烯基或低烷烯基，X代表O或S，虚线表示4位和5位之间的碳-碳键为单键或双键，或其盐；以及含有它们作为有效成分的药物。这些化合物对白细胞介素-1β的产生具有出色的抑制活性，并可用作免疫系统疾病、炎症性疾病、缺血性疾病等的预防和治疗药物。
• Benzylpiperazine derivatives. I. Syntheses and biological activities of 1-(2,3,4-trimethoxybenzyl)piperazine derivatives.
  作者：HIROSHI OHTAKA、MUTSUO MIYAKE、TOSHIRO KANAZAWA、KEIZO ITO、GORO TSUKAMOTO

  DOI：10.1248/cpb.35.2774

  日期：——

  A series of 1- (2, 3, 4-trimethoxybenzyl) piperazine (trimetazidine) derivatives were prepared and tested for cerebral vasodilating activity. Almost all the compounds possess stronger activity than trimetazidine and among them, the γ-amino tertiary alcohols 6e-j exhibit potent cerebral vasodilating activities which are superior to those of cinnarizine and papaverine. Moreover, these compounds show a selective vasodilating effect on vertebral arteries.

  合成了一系列1-（2, 3, 4-三甲氧基苄基）哌嗪（曲美他嗪）衍生物，并测试其脑血管扩张活性。几乎所有化合物的活性均强于曲美他嗪，其中γ-氨基三级醇6e-j表现出强大的脑血管扩张活性，优于辛那利嗪和罂粟碱。此外，这些化合物对椎动脉具有选择性的扩张作用。
• Benzylpiperazine compound and pharmaceutical composition as
  申请人：Kanebo, Ltd.

  公开号：US04742062A1

  公开（公告）日：1988-05-03

  Novel benzylpiperazine compound of the formula: ##STR1## or a pharmaceutically acceptable acid addition salt thereof, which has excellent hypolipidemic activity without undesirable side effect, and a pharmaceutical composition containing the compound as an active ingredient suitable for the prophylaxis and treatment of hyperlipidemia.

  一种新型苄基哌嗪化合物的化学式如下：##STR1## 或其药学上可接受的酸盐，该化合物具有出色的降脂活性，没有不良副作用，并且适用于预防和治疗高脂血症的药物组合物中作为活性成分。
• Imidazole derivatives and salts thereof
  申请人：Burroughs Wellcome Co.

  公开号：US04396771A1

  公开（公告）日：1983-08-02

  1-Substituted-imidazoles of the formula: ##STR1## in which A is selected from the group consisting of straight or branched, saturated or unsaturated, acyclic hydrocarbon radicals of from 1 to 3 carbon atoms and R is ##STR2## wherein n is an integer which is at least 1, and the or each Q substituent, which when n is greater than 1 may be the same or different, is selected from a saturated alkyl group of from 1 to 4 carbon atoms or an unsaturated alkyl group of from 2 to 4 carbon atoms, with the proviso that when A is unsaturated Q may also be selected from alkoxy of from 1 to 4 carbon atoms; halo; trihalomethyl; hydroxy; carboxyl; a salt of such a carboxyl group; carboalkyloxy; carboaryloxy; carboarylalkyloxy; --NR.sup.6 R.sup.7 or --CONR.sup.6 R.sup.7 ; in which R.sup.6 and R.sup.7 may be the same or different and are hydrogen or alkyl of from 1 to 4 carbon atoms; the 1-substituted-imidazole being the free base or an acid addition salt thereof. Methods of preparing the 1-substituted-imidazoles are also provided. The imidazoles have pharmacological properties that make them of use in the treatment of thromboembolic disorders, shock and angina pectoris.

  式子如下：##STR1## 其中，A选自由1到3个碳原子的直链或支链、饱和或不饱和的脂肪烃基团组成的群，R为##STR2## 其中n是至少为1的整数，当n大于1时，每个Q取代基可以相同或不同，选自由1到4个碳原子的饱和烷基或2到4个碳原子的不饱和烷基，但当A为不饱和时，Q还可以选自1到4个碳原子的烷氧基、卤素、三卤甲基、羟基、羧基、该羧基的盐、羧基烷氧基、羧基芳氧基、羧基芳基烷氧基、--NR.sup.6 R.sup.7或--CONR.sup.6 R.sup.7，其中R.sup.6和R.sup.7可以相同或不同，选自氢或1到4个碳原子的烷基；该1-取代咪唑为其自由碱基或酸加合盐。本文还提供了制备1-取代咪唑的方法。这些咪唑具有药理特性，可用于治疗血栓栓塞性疾病、休克和心绞痛。
• Benzylpiperazine compound, preparation thereof, pharmaceutical composition, and use
  申请人：KANEBO, LTD.

  公开号：EP0209843A2

  公开（公告）日：1987-01-28

  A novel benzylpiperazine compound of the formula: or a pharmaceutically acceptable acid addition salt thereof, which has excellent hypolipidemic activity without undesirable side effect, a pharmaceutical composition containing the compound as an active ingredient, preparation of the compound, and its use in the preparation of a pharmaceutical composition for the prophylaxis or treatment of hyperlipidemia.

  一种新颖的式苄基哌嗪化合物： 或其药学上可接受的酸加成盐，该化合物具有优异的降血脂活性，且无不良副作用；一种含有该化合物作为活性成分的药物组合物；该化合物的制备方法；以及该化合物在制备预防或治疗高脂血症的药物组合物中的用途。